Redeye comments on Ultimovacs’ Q1 2024 report, following its INITIUM top-line failure and announced cost-cutting measures.
Redeye cuts its estimates and valuation after Ultimovacs announced that INITIUM failed to show an efficacy advantage of UV1 addition to dual...
Redeye believes that INITUM's failure to show improved efficacy of UV1 addition to double CPI therapy in malignant melanoma represents a maj...
Redeye comments on Ultimovacs’ Q4 2023 report, with the company having confirmed its intention to communicate INITIUM top-line data in March...
Redeye comments on Ultimovacs’ Q3 2023 report, with recently presented NIPU survival data paving UV1’s path to phase III trials in mesotheli...
Redeye judges that more mature NIPU data, indicating OS and ORR benefits of UV1 addition to double CPI therapy, paves the way for late-stage...
Redeye provides a brief initial take on Ultimovacs reporting more granular NIPU data.
Redeye comments on Ultimovacs’ Q2 2023 report, following a quarter in which the company’s share price took a hit due to inconclusive NIPU to...
Redeye comments on Ultimovacs reporting NIPU top-line data, communicating that the phase II trial had not met its primary PFS endpoint.
Redeye provides its comment on Ultimovacs’ Q1 2023 report, which featured no surprises.
Redeye judges that Ultimovacs announcing a slight delay for its phase II INITIUM readout from H1 2023e to H2 2023e does not constitute a maj...
Ultimovacs’ Q422 and FY22 results reflected another busy period marked by continued development of its lead cancer vaccine, UV1, across mult...
Redeye comments on Ultimovacs’ Q4 2022 report, and we judge that INITIUM and NIPU top-line data in H1 2023e will constitute critical catalys...
Ultimovacs has announced that patient enrolment has been completed (n=118) for the ongoing Phase II NIPU study investigating the company’s l...
Ultimovacs has announced that the Phase II LUNGVAC study (NCT05344209) will be switching the immune checkpoint inhibitor (ICI) to be used in...
Ultimovacs has announced the completion of patient enrollment in the Phase I TENDU study in prostate cancer.
Ultimovacs’ Q322 results highlighted an eventful period for the development of the company’s lead cancer vaccine, UV1.
Redeye comments on Ultimovacs’ Q3 2022 report, as the company’s lead candidate is approaching its proverbial ‘moment of truth’ in the form o...
Redeye comments on Ultimovacs reporting a three-year survival OS rate of some 71% for cohort 1 of its UV1-103 study.
Ultimovacs has announced encouraging new data from its completed Phase I study (NCT02275416).
Redeye comments on Ultimovacs’ Q2 2022 report with several potential catalysts on the near- to medium-term horizon.
Redeye briefly comments on Ultimovacs communicating two-year overall survival data from UV-103.
Redeye comments on Ultimovacs’ Q1 report; with patient recruitment for the company’s phase II trials progressing steadily, we judge.
Redeye initiates coverage of Ultimovacs, a Nordic biotech company developing therapeutic cancer vaccines, which we believe has delivered pro...
